John Phillips, MD, FACS
With Expertise in: _
_
- Da Vinci Prostatectomy
- Laparoscopic Adrenal Surgery
- Kidney-Sparing Surgery
- LESS Surgery
- Clinical Trials
_
Dr. Phillips is an NIH-trained specialist in robotic surgery and urologic oncology. He has peformed 100's of robotic procedures including the Da Vinci Prostatectomy, Partial Nephrectomy, and Adrenalectomy. He sits on the steering committee of the Robotic and Laparoscopic Surgery section of the American Urologic Association.
Dr. Phillips graduated from Yale Medical School and trained at Yale-New Haven Hospital. He completed fellowships in laparoscopic cancer surgery and urologic oncology at the National Institutes of Health (NIH) and National Cancer Institute. He is Program Director of the Department of Urology at New York Medical College, Founder of the Robotics Institute of Westchester, and Chief of Robotic Surgery & Genito-Urinary Oncology. Dr. Phillips is a diplomate of the American Board of Urology, a fellow of the New York Academy of Medicine and the American College of Surgeons.
He is a member of the Society of Urologic Oncology, Society of Laparoscopic Surgeons, and the Society of Urology Chairpersons and Program Directors.
He has over 25 publications in urology, urologic oncology, and genetics. He wrote the book, "The Bends: Compressed Air in the History of Diving and Engineering", published by Yale University Press in 1998. He is currently working on the textbook, "A History of Fluid and Electrolyte Therapy".
Dr. Phillips' laboratory work is to develop new treatments for bladder cancer. His laboratory is focused on blocking the bladder cancer causing gene FGFR3.
EDUCATION
Undergraduate: Wesleyan University
Medical School: Yale University
Residency: Yale-New Haven Hospital
FELLOWSHIP
National Cancer Institute (NCI), Bethesda, MD
National Institutes of Health (NIH)
BOARD CERTIFICATION
American Urologic Association (AUA), 2002
POSITIONS
Associate Professor, New York Medical College
Program Director, Urology Residency, NYMC
Fellow, American College of Surgeons
Society of Urologic Oncology
Representative, New York Section of the AUA
AUA Leadership Class 2008
HOSPITALS
Westchester Medical Center, Valhalla, NY
Metropolitan Hospital Center, Manhattan, NY
Phelps Memorial Hospital, Sleepy Hollow, NY
Soundshore Medical Center, New Rochelle, NY
Dr. John Phillips' explanation for what he is doing-
Our group is developing nanotechnology to improve treatments for bladder cancer. The bladder is designed to contain (and not absorb) fluid. The bladder poorly absorbs otherwise effective cancer-killing chemotherapies. Our lab, in collaboration with molecular engineers, is testing a new generation of tiny protein beads which contain a chemotherapy 'bullet' within. The 'Trojan Horse' nano-beads are absorbed by the bladder and, within bladder tissues, release the chemotherapy to kill cancer cells. Clinical trials for patients who have failed traditional bladder cancer therapies are to be developed based on our work. Seize the Ribbon support will fund critical safety and effectiveness analysis, nano-bead design and production, and the inter-disciplinary collaborations required for clinical trials to begin
A more in depth discussion-
Bladder cancer is a highly aggressive and potentially fatal cancer when advanced. Bladder cancers fall into two groups: invasive or non-invasive. Invasive bladder cancer is typically treated with radical surgery, chemotherapy, and radiation, but still has a poor survival rate. Non-invasive bladder cancer is common, the 9th most frequent cancer, and can be curable before the cancer grows to become invasive. Current therapies for non-invasive bladder cancer may fail because the bladder, designed as an almost impervious storage organ, does not readily absorb chemotherapy medications. Our research plan is to design a molecule that can be absorbed by the bladder and deliver a chemotherapy drug into the bladder tissue itself. So called molecules, or nano-particles, may revolutionize all medical therapies, and our plan is to do so in the fight against bladder cancer. Our research design is working to pre-clinical trials for patients who have failed standard therapy for non-invasive cancers and are at risk for disease progression and its consequences.
Research Background: The design of effective cancer drugs requires multiple controls including a model animal system and high-quality drug. We are currently studying a mouse model of bladder cancer in which animals carry mutant DNA for the Uro-Plakin III gene. Uro-Plakin III is an important gene for bladder development but when mutated causes non-invasive bladder cancer in affected animals. The field of nanoparticles is new and requires input from chemical engineers, protein biologists, and pharmacologists. We have collaborated with Immunex, a drug design group, who are developing a novel nanoparticle that contains the chemotherapy drug cisplatin and are to provide the nanoparticles for our work. Our nanoparticle project will involve the in vivo testing of cisplatin-nanoparticles (CP-NPs) in Uro-Plakin III mutated female nude mice. Preliminary results suggest that Uro-Plakin III mutant (UP+) mice all express an early form of bladder cancer called carcinoma in situ (CIS). UP+ mice are determined through DNA analysis of small tissue samples and only UP+ mice are used in the CP-NP experiments. CP-NP also contain a fluorescent ‘tag’ called FITC and this allows for CP-NP-FITC treated mice to be assessed for CP-NP absorption and tissue affects by using whole body fluorescent imaging techniques.
_
Dr. Phillips graduated from Yale Medical School and trained at Yale-New Haven Hospital. He completed fellowships in laparoscopic cancer surgery and urologic oncology at the National Institutes of Health (NIH) and National Cancer Institute. He is Program Director of the Department of Urology at New York Medical College, Founder of the Robotics Institute of Westchester, and Chief of Robotic Surgery & Genito-Urinary Oncology. Dr. Phillips is a diplomate of the American Board of Urology, a fellow of the New York Academy of Medicine and the American College of Surgeons.
He is a member of the Society of Urologic Oncology, Society of Laparoscopic Surgeons, and the Society of Urology Chairpersons and Program Directors.
He has over 25 publications in urology, urologic oncology, and genetics. He wrote the book, "The Bends: Compressed Air in the History of Diving and Engineering", published by Yale University Press in 1998. He is currently working on the textbook, "A History of Fluid and Electrolyte Therapy".
Dr. Phillips' laboratory work is to develop new treatments for bladder cancer. His laboratory is focused on blocking the bladder cancer causing gene FGFR3.
EDUCATION
Undergraduate: Wesleyan University
Medical School: Yale University
Residency: Yale-New Haven Hospital
FELLOWSHIP
National Cancer Institute (NCI), Bethesda, MD
National Institutes of Health (NIH)
BOARD CERTIFICATION
American Urologic Association (AUA), 2002
POSITIONS
Associate Professor, New York Medical College
Program Director, Urology Residency, NYMC
Fellow, American College of Surgeons
Society of Urologic Oncology
Representative, New York Section of the AUA
AUA Leadership Class 2008
HOSPITALS
Westchester Medical Center, Valhalla, NY
Metropolitan Hospital Center, Manhattan, NY
Phelps Memorial Hospital, Sleepy Hollow, NY
Soundshore Medical Center, New Rochelle, NY
Dr. John Phillips' explanation for what he is doing-
Our group is developing nanotechnology to improve treatments for bladder cancer. The bladder is designed to contain (and not absorb) fluid. The bladder poorly absorbs otherwise effective cancer-killing chemotherapies. Our lab, in collaboration with molecular engineers, is testing a new generation of tiny protein beads which contain a chemotherapy 'bullet' within. The 'Trojan Horse' nano-beads are absorbed by the bladder and, within bladder tissues, release the chemotherapy to kill cancer cells. Clinical trials for patients who have failed traditional bladder cancer therapies are to be developed based on our work. Seize the Ribbon support will fund critical safety and effectiveness analysis, nano-bead design and production, and the inter-disciplinary collaborations required for clinical trials to begin
A more in depth discussion-
Bladder cancer is a highly aggressive and potentially fatal cancer when advanced. Bladder cancers fall into two groups: invasive or non-invasive. Invasive bladder cancer is typically treated with radical surgery, chemotherapy, and radiation, but still has a poor survival rate. Non-invasive bladder cancer is common, the 9th most frequent cancer, and can be curable before the cancer grows to become invasive. Current therapies for non-invasive bladder cancer may fail because the bladder, designed as an almost impervious storage organ, does not readily absorb chemotherapy medications. Our research plan is to design a molecule that can be absorbed by the bladder and deliver a chemotherapy drug into the bladder tissue itself. So called molecules, or nano-particles, may revolutionize all medical therapies, and our plan is to do so in the fight against bladder cancer. Our research design is working to pre-clinical trials for patients who have failed standard therapy for non-invasive cancers and are at risk for disease progression and its consequences.
Research Background: The design of effective cancer drugs requires multiple controls including a model animal system and high-quality drug. We are currently studying a mouse model of bladder cancer in which animals carry mutant DNA for the Uro-Plakin III gene. Uro-Plakin III is an important gene for bladder development but when mutated causes non-invasive bladder cancer in affected animals. The field of nanoparticles is new and requires input from chemical engineers, protein biologists, and pharmacologists. We have collaborated with Immunex, a drug design group, who are developing a novel nanoparticle that contains the chemotherapy drug cisplatin and are to provide the nanoparticles for our work. Our nanoparticle project will involve the in vivo testing of cisplatin-nanoparticles (CP-NPs) in Uro-Plakin III mutated female nude mice. Preliminary results suggest that Uro-Plakin III mutant (UP+) mice all express an early form of bladder cancer called carcinoma in situ (CIS). UP+ mice are determined through DNA analysis of small tissue samples and only UP+ mice are used in the CP-NP experiments. CP-NP also contain a fluorescent ‘tag’ called FITC and this allows for CP-NP-FITC treated mice to be assessed for CP-NP absorption and tissue affects by using whole body fluorescent imaging techniques.
_